Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy
Toby A. Eyre(Oxford University Hospitals NHS Trust), Graham P. Collins(Churchill Hospital), Harriet S. Walter(Leicester Royal Infirmary), Matt Cross(Royal Marsden Hospital), Sunil Iyengar(Royal Marsden Hospital), Andrew Hodson(Ipswich Hospital), Josh T. Coats(University of Dundee), Martin J.S. Dyer(University of Leicester), Christopher P. Fox(University of Nottingham), Santosh Narat, George Follows(Addenbrooke's Hospital)
Cited by 137
Related Papers
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2010|587
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
|The Lancet|2021|456
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2023|213